US FDA Advisory Panel Reject Licensure of Pfizer’s Booster Vaccine in People Ages 16 and Older

Translator by: MOS Health Team – Wenfei

September 17th, Friday, due to insufficient clinical data and potential myocarditis risk, the U.S. Food and Drug Administration (FDA) advisory panel rejected licensure of Pfizer’s booster vaccine in people ages 16 and older, at a vote of 2-16; but endorsed emergency approval for the booster shot at least six months following the second dose among people ages 65 and older.

The advisory panel consists of 18 influential experts, including members of the FDA “Vaccines and Related Biological Products Advisory Committee” (VRBPAC), officials from the Centers for Disease Control and Prevention (CDC), officials from the Israeli Ministry of Health, vaccine experts and Pfizer representatives. Experts believe that insufficient data support the booster for the young, especially for males aged 16-17; however, the booster may increase the risk of potential myocarditis.

The COVID-19 vaccine has induced significant damage to the world. With the information suppression on mainstream media and local government, plus the Pfizer behind scene influence, COVID-19 remain spreading worldwide. Luckily, truth revealed by the whistleblower movement leads the vaccine side-effect news starting to appear in public media. More medical experts and officials are more aware of the dangers that vaccines bring about.

Editor by: James Zoebel
Posted by: RonaldS


Formore information, please follow us at:
New York MOS Himalaya |GTV
New York MOS Himalaya |MOS TALK
New York MOS Himalaya | Gettr
New York MOS Himalaya |YouTube
Free to Join New York MOS Himalaya | Discord

Inline Feedbacks
View all comments